Baseline demographics
| Demographic variable | Pooled population |
| Sex M/F (n) | 10/19 |
| Age years (mean±sd) | 54.9±11.4 |
| IPAH/FPAH/CTD (n) | 15/4/10 |
| PVR dyn·s·cm−5 (mean±sd) | 612.30±317.63 |
| mPAP mmHg (mean±sd) | 43.57±11.07 |
| NT-proBNP pg·mL−1 (median (IQR)) | 329.50 (549) |
| Cardiac output L·min−1 (median (IQR)) | 5.14 (2.18) |
| PAH medication (%) | |
| Ambrisentan/bosentan/macitentan | 17.2/6.9/3.4 |
| Sildenafil/tadalafil/riociguat | 58.6/13.8/11.1 |
| 6MWT m (mean±sd) | 425.9±112.1 |
| WHO class II/III (%) | 48.3/51.7 |
M: male; F: female; IPAH: idiopathic pulmonary hypertension; FPAH: familial pulmonary hypertension; CTD: connective tissue disease; PVR: pulmonary vascular resistance; mPAP: mean pulmonary arterial pressure; NT-proBNP: N-terminal pro-brain natriuretic peptide; IQR: interquartile range; 6MWT: 6-min walk test; WHO: World Health Organization.